Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: worthington s. Amyloid. 2020 Sep;27(3):200-205. doi: 10.1080/13506129.2020.1765768. Epub 2020 May 15. Amyloid. 2020. PMID: 32408823 Clinical Trial.
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, Yong K, Popat R, Rabin N, Kyriakou C, Sive J, Esposti SD, Larkin DFP, Worthington S, Hart A, Dowling E, Correia N, Bygrave C, Rydzewski A, Jamroziak K, Wechalekar AD. Khwaja J, et al. Among authors: worthington s. Blood Cancer J. 2022 Sep 5;12(9):128. doi: 10.1038/s41408-022-00717-2. Blood Cancer J. 2022. PMID: 36064540 Free PMC article. No abstract available.
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, Rabin N, Popat R, Kyriakou C, Worthington S, Sharpley F, Smith M, Shah R, Cheesman S, Hawkins PN, Wechalekar AD. Manwani R, et al. Among authors: worthington s. Br J Haematol. 2019 Dec;187(5):638-641. doi: 10.1111/bjh.16122. Epub 2019 Aug 6. Br J Haematol. 2019. PMID: 31388995 Free article.
Standardised practices in the networked management of congenital hyperinsulinism: a UK national collaborative consensus.
Shaikh MG, Lucas-Herald AK, Dastamani A, Salomon Estebanez M, Senniappan S, Abid N, Ahmad S, Alexander S, Avatapalle B, Awan N, Blair H, Boyle R, Chesover A, Cochrane B, Craigie R, Cunjamalay A, Dearman S, De Coppi P, Erlandson-Parry K, Flanagan SE, Gilbert C, Gilligan N, Hall C, Houghton J, Kapoor R, McDevitt H, Mohamed Z, Morgan K, Nicholson J, Nikiforovski A, O'Shea E, Shah P, Wilson K, Worth C, Worthington S, Banerjee I. Shaikh MG, et al. Among authors: worthington s. Front Endocrinol (Lausanne). 2023 Oct 30;14:1231043. doi: 10.3389/fendo.2023.1231043. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027197 Free PMC article. Review.
Reply to RJ Klement.
Lieberman DE, Worthington S, Schell LD, Parkent CM, Devinsky O, Carmody RN. Lieberman DE, et al. Among authors: worthington s. Am J Clin Nutr. 2023 Dec;118(6):1241-1242. doi: 10.1016/j.ajcnut.2023.09.026. Epub 2023 Oct 31. Am J Clin Nutr. 2023. PMID: 38044026 No abstract available.
A Gender Hypothesis of sex disparities in adverse drug events.
Lee KMN, Rushovich T, Gompers A, Boulicault M, Worthington S, Lockhart JW, Richardson SS. Lee KMN, et al. Among authors: worthington s. Soc Sci Med. 2023 Dec;339:116385. doi: 10.1016/j.socscimed.2023.116385. Epub 2023 Nov 8. Soc Sci Med. 2023. PMID: 37952268 Free article.
77 results